gluamet 50 mg/tabl. + 850 mg/tabl. tabletki powlekane
merck sp. z o.o. - vildagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg/tabl. + 850 mg/tabl.
alikval 50 mg tabletki
egis pharmaceuticals plc - vildagliptinum - tabletki - 50 mg
agnis combi 50 mg + 1000 mg tabletki powlekane
belupo lijekovi i kozmetika d.d. - vildagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 1000 mg
agnis combi 50 mg + 850 mg tabletki powlekane
belupo lijekovi i kozmetika d.d. - vildagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 850 mg
agartha 50 mg tabletki
gedeon richter polska sp. z o.o. - vildagliptinum - tabletki - 50 mg
kwikaton 50 mg tabletki
stada arzneimittel ag - vildagliptinum - tabletki - 50 mg
agartha duo 50 mg + 850 mg tabletki powlekane
gedeon richter polska sp. z o.o. - vildagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 850 mg
agartha duo 50 mg + 1000 mg tabletki powlekane
gedeon richter polska sp. z o.o. - vildagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 1000 mg
zomarist
novartis europharm limited - вилдаглиптин, metformina chlorowodorek - diabetes mellitus, type 2 - leki stosowane w cukrzycy - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.
galvus
novartis europharm limited - wildagliptyna - diabetes mellitus, type 2 - leki stosowane w cukrzycy - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.